Management Team


Roger Crystal, MD

Chief Executive Officer

Roger Crystal brings more than 15 years of experience as a healthcare business executive and clinician.  He is a pioneer in the development of intranasal naloxone treatments for opioid overdose.  He led Opiant’s development of nasal naloxone for opioid overdose, which led to FDA approval, and is the lead inventor on the product’s patents.  He served as the Chief Business Officer for ImaginAb, a Los Angeles based venture capital backed biotechnology company, leading the company’s turnaround around its immuno-oncology platform and managed its pharmaceutical company partnerships and licensing deals.  He was responsible for acquisitions, licensing and partnering deals at GE Healthcare.  He began his business career working for Goldman Sachs in Mergers and Acquisitions and as a management consultant at A.T. Kearney specializing in healthcare strategy.  Before business school, he had worked as an ENT surgeon at leading institutions including Imperial College Healthcare, London.  He was awarded Membership of The Royal College of Surgeons of England (MRCS).  He was also an Honorary Research Fellow at University College London and has authored a number of peer-reviewed scientific articles.  Dr. Crystal holds a BMedSci in Physiology and an MD from the University of Birmingham and an MBA from the London Business School.


Phil Skolnick, PhD, DSc (hon.)

Chief Scientific Officer

Phil Skolnick has more than 45 years of pharmaceutical experience, with leadership positions in academia, government and industry.  Prior to Opiant, he served as the Director, Division of Therapeutics and Medical Consequences at the National Institute on Drug Abuse, NIH (2010-2017).  He was Chief Scientific Officer (2001-2009) and President (2007-2009) of DOV Pharmaceutical, Inc.  He was a Lilly Research Fellow (Neuroscience) at Lilly Research Laboratories (1997-2000).  Prior to this, he served as Senior Investigator and Chief, Laboratory of Neuroscience, at the NIH from 1986-1997.  He has also served as a Research Professor of Psychiatry at New York University-Langone Medical Center, Research Professor of Psychiatry at the Uniformed Services University of the Health Sciences, Adjunct Professor of Anesthesiology at Johns Hopkins University, and Adjunct Professor of Pharmacology and Toxicology at Indiana University School of Medicine.  Throughout his career, he has been attached to more than 550 publications in the fields of molecular and clinical neuropsychopharmacology.  Dr. Skolnick received a BS from Long Island University (summa cum laude) and a PhD from the Department of Pharmacology, George Washington University School of Medicine.


Kevin Pollack, JD

Chief Financial Officer

Kevin Pollack has more than 20 years of experience as a financial and legal professional.  Prior to Opiant, he worked in asset management at Paragon Capital LP.  Before that, he was an investment banker at Banc of America Securities LLC.  He began his career as a securities attorney at Sidley Austin LLP (formerly Brown & Wood LLP).  Currently, he serves on the Boards of Directors of MagneGas Corporation and Pressure BioSciences, Inc.  He is also President of Short Hills Capital LLC.  Mr. Pollack holds a BS, magna cum laude, from the Wharton School of the University of Pennsylvania and a JD and MBA from Vanderbilt University, where he graduated with Beta Gamma Sigma honors.


Arvind Agrawal

Executive Vice President, Medical Affairs

Arvind Agrawal has more than 20 years of experience in medical affairs and clinical development.  Prior to Opiant, he was Head of Medical Affairs and New Products at Mundipharma International, where he made significant advances towards the development of a novel treatment for opioid addiction.  Before that, while acting as European Clinical and Scientific Affairs Director at Reckitt Benckiser Pharmaceuticals, he developed strategies leading to positive clinical, political, and legislative changes for the treatment of opioid dependence.  His earlier professional experience included various senior management positions in medical affairs and clinical development at: AstraZeneca plc, GlaxoSmithKline plc, SmithKline Beecham plc, and Wellcome Pharmaceuticals.  There he was instrumental in launching the pharmaceutical blockbusters Crestor (rosuvastatin) and Avandia (rosiglitazone).  Currently, he is the Managing Director of Ekagra Ltd, a pharmaceutical medical affairs consultancy in the U.K.  Mr. Agrawal holds a BSc (Hons) in Physiology from University College and an MSc in Human & Applied Physiology from King’s College, University of London.


Mark Ellison, PhD

Executive Vice President Development, Manufacturing and Quality

Mark Ellison brings more than 20 years of experience in the pharmaceutical industry developing products in the therapeutic areas of gastrointestinal, malignant disease, critical care, respiratory, wound healing and diabetes.  His career focus has been in the areas of product development, regulatory strategy and compliance, quality assurance, clinical development and project management.  Prior to Opiant, he was most recently Head of Technical Affairs at S.L.A. Pharma and has also held management positions at the Medicines and Healthcare products Regulatory Agency (MHRA), Link Pharmaceuticals, DMV International and Merck.  Currently, he is the Director of Phax Pharma, a pharmaceutical consultancy.  Dr. Ellison holds a BSc (Hons) in Pharmacy from the University of Portsmouth and a PhD in pharmaceutical technology from the University of Sunderland.  He is a qualified pharmacist and member of the General Pharmaceutical Council in the U.K.


Quan Vu

Vice President, Corporate Development

Quan Vu has more than 15 years of finance, strategy and corporate development experience in the healthcare space.  Prior to Opiant, he was a Staff Vice President/Chief of Staff at Anthem, responsible for strategy, planning and administration of a $2 billion budget.  Before that, he was a Director in the Strategy, Corporate Development & Finance team at Impax Laboratories, focusing primarily on product licensings and acquisitions in the brand CNS space as well as capital raises and tax inversion strategies.  Prior to Impax, he was part of the Strategy & Corporate Development team at Amgen, working on various biotechnology strategies, divestitures, licensings, joint ventures, collaborations and acquisitions.  Earlier in his career, he spent a number of years in finance, executing multi-billion dollar transactions in the Healthcare Corporate Finance and Mergers & Acquisitions group at bulge bracket investment banks, including Morgan Stanley and Goldman Sachs.  Mr. Vu holds BA in Economics from UCLA, graduating with College, Departmental and Latin Honors (summa cum laude).  He is also a Certified Treasury Professional (inactive).